SCHEMBL3326533

SCHEMBL3326533

CCN(CCCNS(=O)(=O)c1ccc(S(N)(=O)=O)cc1)CCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.64
CA1 P00915 10/20 0.59
CA2 P00918 10/20 0.59
ALDH1A1 P00352 4/20 0.59
USP2 O75604 1/20 0.54
CA12 O43570 9/20 0.52
CA4 P22748 5/20 0.52
TP53 P04637 1/20 0.51
GAA P10253 1/20 0.51
TMEM97 Q5BJF2 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
PRMT1 Q99873 1/20 0.50
CA6 P23280 1/20 0.49
CA5A P35218 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
CA14 Q9ULX7 1/20 0.49
CA5B Q9Y2D0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3324307 0.93 HSD17B10 (0.67) HSD17B10CA1CA2ALDH1A1CA12
SCHEMBL3322300 0.86 USP2 (0.70) HSD17B10CA1CA2ALDH1A1USP2
SCHEMBL3385497 0.85 USP2 (0.61) HSD17B10CA1CA2ALDH1A1USP2
SCHEMBL3322296 0.85 USP2 (0.61) HSD17B10CA1CA2ALDH1A1USP2
SCHEMBL16359721 0.80 USP2 (0.69) CA2ALDH1A1USP2CA12SIGMAR1
SCHEMBL3387320 0.80 SIGMAR1 (0.61) HSD17B10CA1CA2ALDH1A1USP2
SCHEMBL3324244 0.79 USP2 (0.57) HSD17B10CA1CA2ALDH1A1USP2
SCHEMBL3387197 0.79 USP2 (0.57) HSD17B10CA1CA2ALDH1A1USP2
SCHEMBL3323497 0.79 USP2 (0.57) HSD17B10CA1CA2ALDH1A1USP2
SCHEMBL3324949 0.78 SIGMAR1 (0.74) HSD17B10CA1CA2ALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US claimed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP claimed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO claimed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US disclosed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US disclosed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP disclosed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE ARSA, SMS, SULT1E1 HSD17B10 2022/4885CA1 653/4885CA2 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.